Vorasidenib Citrate
Vorasidenib citrate works by entering the brain and blocking the activity of abnormal IDH1 and IDH2 enzymes produced by IDH1 and IDH2 genes with certain mutations. By blocking these enzymes, vorasidenib citrate helps slow or stop the growth of certain types of brain tumors. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Vorasidenib citrate is approved to treat:
- astrocytoma or oligodendroglioma in adults and children aged 12 years and older that is grade 2, has an abnormal IDH1 or IDH2 gene, and has been treated with surgery, including biopsy, to partially or completely remove the tumor.
Vorasidenib citrate is also being studied in the treatment of other types of cancer.
More About Vorasidenib Citrate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Engaging People with Low-Grade Glioma in Cancer Research
Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Vorasidenib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.